Gavestinel does not improve outcome after acute intracerebral hemorrhage

An analysis from the GAIN International and GAIN Americas studies

E. Clarke Haley, John L P Thompson, Bruce Levin, Stephen Davis, Kennedy R. Lees, John G. Pittman, Janet T. DeRosa, Paul Ordronneau, Devin L. Brown, Ralph L Sacco

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background and Purpose - Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and putative neuroprotectant drug administered within 6 hours of suspected ischemic or hemorrhagic stroke. Both trials reported that gavestinel was ineffective in ischemic stroke. This analysis reports the results in those with primary intracerebral hemorrhage. Methods - The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. The BI scores were divided into 3 groups: 95 to 100 (independent), 60 to 90 (assisted independence), and 0 to 55 (dependent) or dead. Results - In total, 3450 patients were randomized in GAIN International (N = 1804) and GAIN Americas (N = 1646). Of these, 571 were ultimately identified to have spontaneous intracerebral hematoma on baseline head computerized tomography scan. The difference in distribution of trichotomized BI scores at 3 months between gavestinel and placebo was not statistically significant (P=0.09). Serious adverse events were reported at similar rates in the 2 treatment groups. Conclusions - These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. These findings are similar to results previously reported in patients with ischemic stroke.

Original languageEnglish
Pages (from-to)1006-1010
Number of pages5
JournalStroke
Volume36
Issue number5
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Cerebral Hemorrhage
Glycine
Stroke
Placebos
Patient Harm
Neuroprotective Agents
3-(2-((phenylamino)carbonyl)ethenyl)-4,6-dichloroindole-2-carboxylic acid
Neuroprotection
Hematoma
Randomized Controlled Trials
Head
Tomography
Therapeutics
Pharmaceutical Preparations

Keywords

  • Hemorrhage
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Gavestinel does not improve outcome after acute intracerebral hemorrhage : An analysis from the GAIN International and GAIN Americas studies. / Haley, E. Clarke; Thompson, John L P; Levin, Bruce; Davis, Stephen; Lees, Kennedy R.; Pittman, John G.; DeRosa, Janet T.; Ordronneau, Paul; Brown, Devin L.; Sacco, Ralph L.

In: Stroke, Vol. 36, No. 5, 01.05.2005, p. 1006-1010.

Research output: Contribution to journalArticle

Haley, EC, Thompson, JLP, Levin, B, Davis, S, Lees, KR, Pittman, JG, DeRosa, JT, Ordronneau, P, Brown, DL & Sacco, RL 2005, 'Gavestinel does not improve outcome after acute intracerebral hemorrhage: An analysis from the GAIN International and GAIN Americas studies', Stroke, vol. 36, no. 5, pp. 1006-1010. https://doi.org/10.1161/01.STR.0000163053.77982.8d
Haley, E. Clarke ; Thompson, John L P ; Levin, Bruce ; Davis, Stephen ; Lees, Kennedy R. ; Pittman, John G. ; DeRosa, Janet T. ; Ordronneau, Paul ; Brown, Devin L. ; Sacco, Ralph L. / Gavestinel does not improve outcome after acute intracerebral hemorrhage : An analysis from the GAIN International and GAIN Americas studies. In: Stroke. 2005 ; Vol. 36, No. 5. pp. 1006-1010.
@article{c7f4754b386540cb89065975f008671b,
title = "Gavestinel does not improve outcome after acute intracerebral hemorrhage: An analysis from the GAIN International and GAIN Americas studies",
abstract = "Background and Purpose - Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and putative neuroprotectant drug administered within 6 hours of suspected ischemic or hemorrhagic stroke. Both trials reported that gavestinel was ineffective in ischemic stroke. This analysis reports the results in those with primary intracerebral hemorrhage. Methods - The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. The BI scores were divided into 3 groups: 95 to 100 (independent), 60 to 90 (assisted independence), and 0 to 55 (dependent) or dead. Results - In total, 3450 patients were randomized in GAIN International (N = 1804) and GAIN Americas (N = 1646). Of these, 571 were ultimately identified to have spontaneous intracerebral hematoma on baseline head computerized tomography scan. The difference in distribution of trichotomized BI scores at 3 months between gavestinel and placebo was not statistically significant (P=0.09). Serious adverse events were reported at similar rates in the 2 treatment groups. Conclusions - These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. These findings are similar to results previously reported in patients with ischemic stroke.",
keywords = "Hemorrhage, Neuroprotection, Stroke",
author = "Haley, {E. Clarke} and Thompson, {John L P} and Bruce Levin and Stephen Davis and Lees, {Kennedy R.} and Pittman, {John G.} and DeRosa, {Janet T.} and Paul Ordronneau and Brown, {Devin L.} and Sacco, {Ralph L}",
year = "2005",
month = "5",
day = "1",
doi = "10.1161/01.STR.0000163053.77982.8d",
language = "English",
volume = "36",
pages = "1006--1010",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Gavestinel does not improve outcome after acute intracerebral hemorrhage

T2 - An analysis from the GAIN International and GAIN Americas studies

AU - Haley, E. Clarke

AU - Thompson, John L P

AU - Levin, Bruce

AU - Davis, Stephen

AU - Lees, Kennedy R.

AU - Pittman, John G.

AU - DeRosa, Janet T.

AU - Ordronneau, Paul

AU - Brown, Devin L.

AU - Sacco, Ralph L

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Background and Purpose - Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and putative neuroprotectant drug administered within 6 hours of suspected ischemic or hemorrhagic stroke. Both trials reported that gavestinel was ineffective in ischemic stroke. This analysis reports the results in those with primary intracerebral hemorrhage. Methods - The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. The BI scores were divided into 3 groups: 95 to 100 (independent), 60 to 90 (assisted independence), and 0 to 55 (dependent) or dead. Results - In total, 3450 patients were randomized in GAIN International (N = 1804) and GAIN Americas (N = 1646). Of these, 571 were ultimately identified to have spontaneous intracerebral hematoma on baseline head computerized tomography scan. The difference in distribution of trichotomized BI scores at 3 months between gavestinel and placebo was not statistically significant (P=0.09). Serious adverse events were reported at similar rates in the 2 treatment groups. Conclusions - These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. These findings are similar to results previously reported in patients with ischemic stroke.

AB - Background and Purpose - Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and putative neuroprotectant drug administered within 6 hours of suspected ischemic or hemorrhagic stroke. Both trials reported that gavestinel was ineffective in ischemic stroke. This analysis reports the results in those with primary intracerebral hemorrhage. Methods - The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. The BI scores were divided into 3 groups: 95 to 100 (independent), 60 to 90 (assisted independence), and 0 to 55 (dependent) or dead. Results - In total, 3450 patients were randomized in GAIN International (N = 1804) and GAIN Americas (N = 1646). Of these, 571 were ultimately identified to have spontaneous intracerebral hematoma on baseline head computerized tomography scan. The difference in distribution of trichotomized BI scores at 3 months between gavestinel and placebo was not statistically significant (P=0.09). Serious adverse events were reported at similar rates in the 2 treatment groups. Conclusions - These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. These findings are similar to results previously reported in patients with ischemic stroke.

KW - Hemorrhage

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=20244368524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244368524&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000163053.77982.8d

DO - 10.1161/01.STR.0000163053.77982.8d

M3 - Article

VL - 36

SP - 1006

EP - 1010

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -